Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors

Area of Science:

• Immunology
• Cancer Biology
• Gene Therapy

Background:

• Natural killer (NK) cells are crucial for tumor immunotherapy due to their ability to kill cancer cells without prior sensitization.
• Tumor cells can evade NK cell attacks through immune escape mechanisms.
• Chimeric antigen receptors (CARs) can be engineered into NK cells to enhance tumor-specific targeting and overcome immune evasion.

Purpose of the Study:

• To identify the most effective method for modifying human NK cells for cancer immunotherapy.
• To compare different retroviral vector systems, pseudotypes, and transduction protocols for NK cell modification.
• To assess the impact of modification on NK cell function and cytotoxicity.

Main Methods:

• Comparison of various retroviral vector systems, pseudotypes, and transduction protocols for modifying primary human NK cells.
• Evaluation of transduction efficiency, receptor expression, and degranulation activity post-modification.
• Assessment of anti-CD19 CAR-engineered NK cell cytotoxicity against CD19-expressing leukemia cells.

Main Results:

• Optimized conditions using alpharetroviral vectors achieved high transduction levels (up to 60%) in human NK cells.
• Alpharetroviral modification did not negatively impact NK cell receptor expression or degranulation activity.
• Anti-CD19 CAR-NK cells demonstrated significantly enhanced and selective cytotoxicity against CD19-positive leukemia cells, leading to near-complete elimination within 48 hours.

Conclusions:

• Alpharetroviral vectors provide an efficient means for genetically modifying human NK cells.
• Engineered anti-CD19 CAR-NK cells show potent anti-leukemia activity.
• Alpharetroviral vectors represent a promising platform for developing NK cell-based cancer immunotherapies.